TABLE 2.

Enrollment characteristics of women included in the recurrence cohort, by vaccination arm

Variables	Control arm, n (%)	HPV arm, n (%)
Number of women	169	142
Age at entry, years
<20	37 (21.9%)	31 (21.8%)
20–21	38 (22.5%)	36 (25.3%)
22–23	53 (31.4%)	38 (26.8%)
>23	41 (24.3%)	37 (26.1%)
Lifetime no. partners
Unknown	2 (1.2%)	0 (0.0%)
Virgin	15 (8.9%)	3 (2.1%)
1	48 (28.4%)	33 (23.2%)
2	40 (23.7%)	42 (29.6%)
3+	64 (37.9%)	64 (45.1%)
Cytology result
Inadequate	1 (0.6%)	2 (1.4%)
Normal	97 (57.4%)	57 (40.1%)
LSIL	31 (18.3%)	36 (25.4%)
HSIL+	40 (23.7%)	47 (33.1%)
HPV DNA (Hierarchical - HPV-16/18, HPV-31/33/45, Other-onco, Non-onco, Negative)
Negative	34 (20.1%)	13 (9.2%)
HPV 16/18-positive	64 (37.9%)	55 (38.7%)
HPV 31/33/45-positive	19 (11.2%)	24 (16.9%)
Other oncogenic-positive	33 (19.5%)	36 (25.4%)
Nononcogenic-positive	19 (11.2%)	14 (9.9%)

HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion.